

Patent Docket No. 220002065000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Eliezer MASLIAH et al.

Serial No.: 09/806,842

Filing Date: October 6, 1999 (Int'l)

For: METHOD FOR SCREENING FOR

ANTI-AMYLOIDOGENIC PROPERTIES AND METHOD FOR TREATMENT OF NEURODEGENERATIVE DISEASE Examiner: S. Standley

Group Art Unit: 1649

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

The documents listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on May 3, 2000, directed to a counterpart international or foreign application and have not been previously cited.

	This information pisotosate statement is submitted.				
	With the application; accordingly, no fee or separate requirements are required.				
\boxtimes	Before the mailing of a first Office Action after the filing of a Request for Continued				
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97				
	(e)(1) has been provided.				
	Within three months of the application filing date or before mailing of a first Office Action				
	on the merits; accordingly, no fee or separate requirements are required. However, if				
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.				
	After receipt of a first Office Action on the merits but before mailing of a final Office Action				
	or Notice of Allowance.				
	A fee is required. A check in the amount of is enclosed.				
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to				
	this submission in duplicate.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is				
	believed to be due.				
	After mailing of a final Office Action or Notice of Allowance, but before payment of the				
	issue fee.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the				
	amount of is enclosed.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal				

This Information Disclosure Statement is submitted.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

form (PTO/SB/17 is attached to this submission in duplicate.)

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 220002065000.

Dated: November 2, 2006

Respectfully submitted,

James J. Mullen III, Ph.D.

Registration No.: 44,957

MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100 San Diego, California 92130-2040

(858) 720-7940

Complete if Known Substitute for form 1449/PTO 09/806,842 Application Number Filing Date October 6, 1999 (Int'I) INFORMATION DISCLOSURE First Named Inventor Eliezer MASLIAH STATEMENT BY APPLICANT 1649 Art Unit (Use as many sheets as necessary) Examiner Name S. Standley 1 220002065000 Sheet 1 Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	1101110 011 01011100 01	Pages, Columns, Lines, Where	
		Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]	
	1.	EP-0 980 727	04/1999				

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	2.	International Search Report for PCT/US99/23134, mailed on 3 May 2000, 6 pages	Ĺ				
	3.	JENNER and OLANOW, Ann. Neurol. (1998) 44(Suppl. 1):S72-S84					
	4.	MIZUNO et al., Ann. Neurol. (1998) 44(Suppl. 1):S99-S109					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Dat	te	
Signature	Cor	nsidered	

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.